

## ***“Risky Business: Invasive Fungal Infections in HSCT”***

### **CME/CE POST ASSESSMENT AND EVALUATION FORM**

---

Release Date: June 5, 2008

Expiration Date: June 5, 2009

#### **Instructions for Receiving Credit**

- Please select the most appropriate answer to questions stated in the Post Assessment Section.
- Print the Evaluation Form (page 2) and complete it, including stating the answers to the Post Assessment questions.
- Fax or mail the completed Evaluation Form to:
  - (414) 456-6623 or Office of Continuing & Professional Education, Medical College of Wisconsin (RPC 125), 8701 Watertown Plank Road, Milwaukee, WI 53226 (**Physician learners refer MCW CME Program ID No. 08151**)
  - (678) 584-9661 or Department of Continuing Education, Syntaxx Communications, 305 West Country Drive, Duluth, GA 30097-5906 (**Pharmacist learners**)
- A CME Certificate or Statement of Credit will be mailed 4–6 weeks upon receipt of materials.

#### **Post Assessment**

1. A rapid diagnostic technique to identify *albicans* vs non-*albicans* *Candida* species is:
  - a.  $\beta$ -D-glucan
  - b. PNA FISH™
  - c. Galactomannan assay
  - d. Gram stain
  
2. The recommended therapy for *C. krusei* infection is:
  - a. Fluconazole
  - b. Voriconazole
  - c. Itraconazole
  - d. Echinocandin
  
3. Which antifungal agent was shown to be superior to amphotericin B for the treatment of invasive aspergillosis?
  - a. Caspofungin
  - b. Micafungin
  - c. Voriconazole
  - d. Posaconazole
  
4. In patients with GVHD undergoing antifungal prophylaxis, which of the following was associated with a significantly lower mortality compared to fluconazole?
  - a. Voriconazole
  - b. Posaconazole
  - c. Micafungin
  - d. Anidulafungin

**“Risky Business: Invasive Fungal Infections in HSCT”**

**CME/CE POST ASSESSMENT AND EVALUATION FORM**

---

**Evaluation Form**

**Answer Key**

1 \_\_\_\_\_ 2 \_\_\_\_\_ 3 \_\_\_\_\_ 4 \_\_\_\_\_

**Please check your professional title:**

Physician                       Pharmacist/PharmD                       Other \_\_\_\_\_

**Objectives**

- Recognize vital risk factors for invasive fungal infections, as well as the time-dependent significance of specific fungal pathogens in the development of infection
- Discuss the updated NCCN guidelines for prevention and treatment of invasive fungal infections in HSCT recipients
- Explain how these updates, including new therapeutics, will impact prophylaxis and the treatment of invasive fungal infections in HSCT recipients

**This activity (please check all that apply):**

- met stated objectives.
- is relevant to my practice of medicine.
- will improve my ability to provide excellent patient care.
- was free of commercial bias.

**The content presented was:**  Excellent  Very Good  Good  Fair  Poor

**The audiovisuals were:**  Excellent  Very Good  Good  Fair  Poor

**What information did you acquire that you plan to use on the job?**

\_\_\_\_\_

\_\_\_\_\_

**What was the best feature of the activity?**

\_\_\_\_\_

\_\_\_\_\_

**What are your suggestions for improvement?**

\_\_\_\_\_

\_\_\_\_\_

**What topics would you recommend be included in future educational program planning?**

\_\_\_\_\_

\_\_\_\_\_

**Credit Application**

Name and degree(s) \_\_\_\_\_

Institution \_\_\_\_\_

Address (for Certificate) \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_

E-mail (if applicable) \_\_\_\_\_ Credits claimed (if less than maximum) \_\_\_\_\_

Indicate whether you need:     **CME** credits for physicians     **Contact Hour** credits for pharmacists